Phaseline

Targets › IFNA1

IFNA1 (Interferon alpha-1): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 1, 1 Phase 3, 1 Phase 4; Infectious disease, Oncology; next expected readout Dec 2026.

Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. (UniProt, P0DY56)

Open in Phaseline: the race on IFNA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
First Affiliated Hospital of Wenzhou Medical UniversityPeg-Interferon α
Type I interferon receptor agonist with antiviral and immunomodulatory activity
IFNA1Phase 4Nonalcoholic Fatty Liver DiseaseDec 2028
Kexing BiopharmHuman interferon α1b Inhalation Solution
Interferon alpha-1b, antiviral cytokine
IFNA1Phase 3Respiratory Syncytial Virus InfectionsJun 2027
Chinese PLA General HospitalMSC-IFNα
Interferon alpha-expressing mesenchymal stromal cells
IFNA1Phase 1Locally Advanced or Metastatic Solid TumorsDec 2026
University of UtahPegylated interferon alpha2a
Type I interferon receptor agonist
IFNA1Phase 1MyelofibrosisJan 2027

Conditions

Respiratory Syncytial Virus Infections (1) Myelofibrosis (1) Locally Advanced or Metastatic Solid Tumors (1) Nonalcoholic Fatty Liver Disease (1)

Modalities

protein or peptide (3), mixed (1)

Companies

Kexing Biopharm (1) University of Utah (1) Chinese PLA General Hospital (1) First Affiliated Hospital of Wenzhou Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.